SCHEMBL6630738

SCHEMBL6630738

CC(=O)N(C)C1[CH]Cc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HTR2A P28223 4/20 0.38
HRH1 P35367 4/20 0.38
ALDH1A1 P00352 1/20 0.38
XBP1 P17861 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.36
POLB P06746 1/20 0.35
NOTUM Q6P988 1/20 0.34
MAPT P10636 1/20 0.34
MTNR1B P49286 2/20 0.33
MTNR1A P48039 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
CHRM1 P11229 1/20 0.33
DRD2 P14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17835755 0.78 HTR2A (0.44) HTR2AHRH1CHRM1DRD2ADRA2B
SCHEMBL5969847 0.70 ALDH1A1 (0.57) MEN1KMT2AALDH1A1XBP1HTT
SCHEMBL5969786 0.70 ALDH1A1 (0.57) MEN1KMT2AALDH1A1XBP1HTT
SCHEMBL4859756 0.69 NPY5R (0.55) MEN1KMT2ASMN1; SMN2TDP1HTR2A
SCHEMBL6634791 0.69 MTNR1A (0.46) SMN1; SMN2ALDH1A1HTTNOTUMMTNR1B
SCHEMBL659024 0.68 ALDH1A1 (0.70) MEN1KMT2AALDH1A1XBP1HTT
SCHEMBL14299385 0.68 ALDH1A1 (0.70) MEN1KMT2AALDH1A1XBP1HTT
SCHEMBL12269912 0.67 ALDH1A1 (0.41) MEN1KMT2ASMN1; SMN2TDP1HTR2A
SCHEMBL8180890 0.66 TSHR (0.42) SMN1; SMN2ALDH1A1HTTNOTUMMAPT
SCHEMBL12269618 0.66 ALDH1A1 (0.38) MEN1KMT2ATDP1ALDH1A1XBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317459-B1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2004-04-07 EP disclosed
US-20030232875-A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors ASTRAZENECA AB (SE) 2003-12-18 US disclosed
EP-1317459-A1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS AstraZeneca AB (SE) 2003-06-11 EP disclosed
WO-2002020530-A1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232875-A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors GYS1, GYS2, PYGL MEN1 4601/4885KMT2A 2910/4885SMN1; SMN2 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.